BG46005A3 - Метод за получаване на експресионен плазмид за експресия на хетероложен ген - Google Patents

Метод за получаване на експресионен плазмид за експресия на хетероложен ген

Info

Publication number
BG46005A3
BG46005A3 BG078443A BG7844381A BG46005A3 BG 46005 A3 BG46005 A3 BG 46005A3 BG 078443 A BG078443 A BG 078443A BG 7844381 A BG7844381 A BG 7844381A BG 46005 A3 BG46005 A3 BG 46005A3
Authority
BG
Bulgaria
Prior art keywords
heterologous gene
promoter
gene
stranded dna
selectable characteristic
Prior art date
Application number
BG078443A
Other languages
Bulgarian (bg)
English (en)
Inventor
Dennis Kleid
Daniel Yansura
Herbert Heyneker
Giuseppe Miozzari
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BG46005A3 publication Critical patent/BG46005A3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BG078443A 1980-03-24 1981-03-03 Метод за получаване на експресионен плазмид за експресия на хетероложен ген BG46005A3 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13329680A 1980-03-24 1980-03-24

Publications (1)

Publication Number Publication Date
BG46005A3 true BG46005A3 (bg) 1989-09-15

Family

ID=22457906

Family Applications (3)

Application Number Title Priority Date Filing Date
BG078443A BG46005A3 (bg) 1980-03-24 1981-03-03 Метод за получаване на експресионен плазмид за експресия на хетероложен ген
BG078444A BG45220A3 (bg) 1980-03-24 1981-03-23 Метод за разцепване на двойноусукана днк
BG051341A BG42526A3 (bg) 1980-03-24 1981-03-23 Метод за получаване на полипептид чрез експресия в бактерий на структурен ген

Family Applications After (2)

Application Number Title Priority Date Filing Date
BG078444A BG45220A3 (bg) 1980-03-24 1981-03-23 Метод за разцепване на двойноусукана днк
BG051341A BG42526A3 (bg) 1980-03-24 1981-03-23 Метод за получаване на полипептид чрез експресия в бактерий на структурен ген

Country Status (35)

Country Link
US (2) US5888808A (enExample)
EP (3) EP0154133B1 (enExample)
JP (3) JPH0724582B2 (enExample)
KR (2) KR830005351A (enExample)
AR (1) AR248050A1 (enExample)
AT (3) ATE52802T1 (enExample)
AU (3) AU542640B2 (enExample)
BG (3) BG46005A3 (enExample)
BR (1) BR8101712A (enExample)
CA (2) CA1198068A (enExample)
CS (3) CS238646B2 (enExample)
DD (3) DD203746A5 (enExample)
DE (5) DE3176205D1 (enExample)
DK (1) DK173085B1 (enExample)
DZ (1) DZ278A1 (enExample)
ES (3) ES500617A0 (enExample)
FI (3) FI853488A7 (enExample)
FR (2) FR2480781B1 (enExample)
GB (1) GB2073203B (enExample)
GR (1) GR74818B (enExample)
HU (1) HU195534B (enExample)
IE (3) IE51894B1 (enExample)
IL (3) IL71885A (enExample)
IT (1) IT1144324B (enExample)
MX (1) MX7689E (enExample)
MY (1) MY8500896A (enExample)
NO (3) NO810986L (enExample)
NZ (3) NZ207659A (enExample)
OA (1) OA06774A (enExample)
PH (4) PH17537A (enExample)
PL (2) PL147727B1 (enExample)
PT (1) PT72716B (enExample)
YU (2) YU45534B (enExample)
ZA (1) ZA811368B (enExample)
ZW (1) ZW5481A1 (enExample)

Families Citing this family (373)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1202581A (en) * 1980-03-27 1986-04-01 Saran A. Narang Adaptor molecules for dna and their application to synthesis of gene-derived products
CA1341604C (en) 1980-04-03 2010-05-04 Biogen N.V. Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
US4874702A (en) * 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
DK489481A (da) * 1980-11-10 1982-05-11 Searle & Co Plasmidvektor og frmgangsmaade til fremstilling deraf
US5525484A (en) * 1981-01-16 1996-06-11 Genome Therapeutics Corp. Recombinant DNA means and method for producing rennin, prorenin and pre-prorennin
BR8205954A (pt) * 1981-10-14 1983-09-13 Unilever Nv Sequencia de dna,plasmidio recombinante,cultura bacteriana e microorganismos
JPS58110600A (ja) * 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS58141796A (ja) * 1982-02-18 1983-08-23 Kyowa Hakko Kogyo Co Ltd ペプチドの製造法
EP0088994B1 (en) * 1982-03-15 1991-06-19 Schering Corporation Hybrid dna, binding composition prepared thereby and processes therefor
US4499188A (en) * 1982-05-05 1985-02-12 Cetus Corporation Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US4863855A (en) * 1982-05-14 1989-09-05 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
EP0108045B1 (en) * 1982-10-25 1988-12-07 Monsanto Company Reca promoter dependent polypeptide production
CA1252046A (en) * 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DK161152C (da) 1983-03-03 1991-11-11 Genentech Inc Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
JP2595205B2 (ja) * 1984-02-08 1997-04-02 カロイン コーポレイション 発現カセット
US5028531A (en) * 1984-03-19 1991-07-02 Fujisawa Pharmaceutical Company, Ltd. IGF-I fusion proteins; protection of IGF-I from degradation by host cell; and processes for the production thereof
GB8407044D0 (en) * 1984-03-19 1984-04-26 Fujisawa Pharmaceutical Co Producing human insulin
US4656132A (en) * 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4894334A (en) * 1984-03-28 1990-01-16 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US5268278A (en) * 1984-03-30 1993-12-07 Istituto Farmacologico Serono S.P.A. Genetic expression of somatostatin as hybrid polypeptide
US4789702A (en) * 1984-05-18 1988-12-06 Cetus Corporation Feline leukemia virus vaccine
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
EP0165613B1 (en) * 1984-06-22 1992-01-15 Hitachi, Ltd. Process for controlling culture of recombinants
JPS619282A (ja) * 1984-06-22 1986-01-16 Hitachi Ltd 遺伝子組換え菌の培養方法
EP0178764A1 (en) * 1984-08-28 1986-04-23 Genex Corporation Method of stabilizing a host microorganism/expression vector system for large scale production of proteins
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US5075224A (en) * 1984-10-19 1991-12-24 Genentech, Inc. Prepro-LHRH C-terminal peptide DNA
NZ213759A (en) * 1984-10-19 1989-01-27 Genentech Inc Lhrh-ctp protein conjugates influencing prolactin fsh and lh release
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0211047B1 (en) 1985-01-28 1994-02-02 Xoma Corporation Arab promoters and method of producing polypeptides, includinn cecropins, by microbiological techniques
IT1234977B (it) * 1985-03-22 1992-06-09 Serono Ist Farm Espressione in e. coli polipeptidi ibridi contenenti la sequenza del fattore di rilascio dell'ormone della crescita
DK171161B1 (da) * 1985-03-28 1996-07-08 Hoffmann La Roche Fremgangsmåde til påvisning af forekomst eller fravær af mindst én specifik nukleinsyresekvens i en prøve eller til skelnen mellem to forskellige nukleinsyresekvenser i denne prøve
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
GB8509289D0 (en) * 1985-04-11 1985-05-15 Fujisawa Pharmaceutical Co Production of somatostatin
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
EP0213472A1 (en) * 1985-08-12 1987-03-11 Syntex (U.S.A.) Inc. Method for producing fusion proteins
AU6104586A (en) * 1985-08-12 1987-02-19 Malcolm A. Martin Aids protein using trple gene
JPH0775536B2 (ja) * 1986-03-26 1995-08-16 猛 小林 遺伝子組み換え菌を用いた酵素生産装置
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
JPH01247098A (ja) * 1988-03-30 1989-10-02 Hitachi Ltd ヒトの上皮細胞増殖因子の遺伝子工学的生産方法
EP0335400B1 (en) * 1988-03-30 1994-06-08 Hitachi, Ltd. Processes for production of human epidermal growth factor by genetic engineering
JPH01247099A (ja) * 1988-03-30 1989-10-02 Hitachi Ltd ヒトの上皮細胞増殖因子の遺伝子工学的生産方法
JPH0227993A (ja) * 1988-07-15 1990-01-30 Nippon Shinyaku Co Ltd ｈＥＧＦの製法
IL92937A0 (en) 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0574402B2 (en) 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
EP0643772B1 (en) 1992-06-03 1997-07-23 Genentech, Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6455304B1 (en) 1994-07-01 2002-09-24 The Board Of Regents Of The University Of Oklahoma Hyaluronate synthase gene and uses thereof
US6951743B2 (en) 1997-10-31 2005-10-04 University Of Oklahoma Board Of Regents Hyaluronan synthase genes and expression thereof in bacillus hosts
US7091008B1 (en) 1994-07-01 2006-08-15 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthase genes and expression thereof in Bacillus hosts
US6077510A (en) * 1995-01-06 2000-06-20 Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6113905A (en) * 1995-01-06 2000-09-05 The Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6015660A (en) * 1995-01-06 2000-01-18 The Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
PT1666591E (pt) 1995-06-29 2011-06-01 Immunex Corp Citoquina que induz apoptose
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
JP2000507829A (ja) 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド Ａｐｏ―２ｌｉおよびａｐｏ―３アポトーシスポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
WO2000039297A2 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
WO1999021999A2 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 inducible genes
CA2572503A1 (en) * 1997-04-04 1998-10-15 University Of Southern California Method for electrochemical fabrication including enhanced data manipulation
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
WO1998055615A1 (en) 1997-06-05 1998-12-10 The University Of Texas Board Or Regents Apaf-1, the ced-4 human homolog, an activator of caspase-3
EP2083079A1 (en) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
PT1007546E (pt) 1997-08-27 2009-04-24 Childrens Hosp & Res Ct Oak Compostos miméticos moleculares de epítopos de meningococos do serogrupo b
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
PT1015587E (pt) 1997-09-18 2008-07-31 Genentech Inc Polipéptido dcr3, um homólogo de tnfr
ATE424459T1 (de) 1997-10-10 2009-03-15 Genentech Inc Apo-3 ligand
JP2003533164A (ja) 1997-10-29 2003-11-11 ジェネンテック・インコーポレーテッド Ｗｎｔ−１誘導分泌ポリペプチド：ＷＩＳＰ−１，−２及び−３
CN1322121C (zh) 1997-10-31 2007-06-20 俄克拉何马大学董事会 透明质酸合酶基因及其应用
CN101113436B (zh) 1997-10-31 2013-02-06 俄克拉何马大学董事会 透明质酸合酶基因及其应用
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
ATE393786T1 (de) 1997-11-21 2008-05-15 Genentech Inc Mit a33 vewandte antigene und deren pharmezeutische verwendung
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
ATE411385T1 (de) 1998-01-15 2008-10-15 Genentech Inc Apo-2 ligand
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
US6987023B2 (en) 1998-04-02 2006-01-17 The Board Of Regents Of The University Of Oklahoma DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
US7223571B2 (en) 1998-04-02 2007-05-29 The Board Of Regents Of The Universtiy Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20060188966A1 (en) 1998-04-02 2006-08-24 Deangelis Paul L Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP2333069A3 (en) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1105485B1 (en) 1998-08-21 2006-07-05 Immunex Corporation Human il-1 epsilon dna and polypeptides
WO2000014265A1 (en) 1998-09-03 2000-03-16 Bristol-Myers Squibb Co. Enzymatic oxidative deamination process
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
US7094581B2 (en) 1998-10-26 2006-08-22 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthases and methods of making and using same
WO2000036118A2 (en) 1998-12-16 2000-06-22 Chiron Corporation HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
EP1820859B9 (en) 1998-12-22 2009-10-28 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
DE60043322D1 (de) 1999-06-15 2009-12-24 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2308974A3 (en) 1999-10-14 2011-08-10 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
IL148936A0 (en) 1999-10-20 2002-09-12 Genentech Inc Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
PT2275553E (pt) 1999-10-29 2015-09-18 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
WO2001033944A1 (en) 1999-11-10 2001-05-17 University Of Washington Compositions and methods for modulation of plant cell division
EP1686134A3 (en) 1999-12-01 2006-08-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP5148795B2 (ja) 1999-12-20 2013-02-20 イミュネックス・コーポレーション Ｔｗｅａｋ受容体
DK1897947T3 (da) 1999-12-23 2012-04-10 Genentech Inc IL-17-homologe polypeptider og terapeutiske anvendelser deraf
CA2395617C (en) 1999-12-30 2012-10-30 Genencor International, Inc. Trichoderma reesei xylanase
AU2001229367A1 (en) 2000-01-10 2001-07-24 Chiron Corporation Genes differentially expressed in breast cancer
DK1246917T3 (da) 2000-01-13 2009-06-08 Genentech Inc Humane Stra6-polypeptider
MXPA02006962A (es) 2000-01-17 2002-12-13 Chiron Spa Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b.
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
DE60124080T2 (de) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
AU2001273094A1 (en) 2000-06-30 2002-01-14 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
EP1671981A3 (en) 2000-10-27 2006-07-05 Chiron SRL. Nucleic acids and proteins from streptococcus group A
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
IL158380A0 (en) 2001-04-16 2004-05-12 Wyeth Corp Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
JP2005500319A (ja) 2001-06-27 2005-01-06 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
ES2386346T3 (es) 2001-08-29 2012-08-17 Genentech, Inc. Ácidos nucleicos y polipéptidos Bv8 con actividad mitógena
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
DE60233347D1 (de) 2001-12-19 2009-09-24 Univ Chicago Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung
WO2003057160A2 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
AU2003243316A1 (en) 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
AU2003239865A1 (en) 2002-05-24 2003-12-12 Restoragen Inc. Method for universal enzymatic production of bioactive peptides
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP2430923A1 (en) 2002-06-05 2012-03-21 Genentech, Inc. Compositions and methods for liver growth and liver protection
KR20050004914A (ko) 2002-06-07 2005-01-12 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
EP2383278A1 (en) 2002-07-08 2011-11-02 Genentech, Inc. Method to determine B cell mediated diseases
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US20060199181A1 (en) 2002-09-11 2006-09-07 Genentch, Inc. Compositions and methods for the treatment of immune related diseases
CA2498274A1 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
BR0314979A (pt) 2002-10-04 2005-08-02 Firmenich & Cie ácido nucleico isolado, polipeptìdeo, vetor, célula hospedeira, organismo não humano, e, métodos de fabricar uma célula hospedeira recombinante, de produzir um polipeptìdeo, de fabricar pelo menos uma sesquiterpeno sintase, e de fabricar pelo menos um terpenóide
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
EP1581169A4 (en) 2002-11-08 2008-09-17 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO NATURAL KILLER CELLS
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2011516026A (ja) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
KR101294959B1 (ko) 2003-03-12 2013-08-09 제넨테크, 인크. 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의 용도
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP2392582A3 (en) 2003-04-25 2012-03-07 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
ATE504645T1 (de) 2003-06-23 2011-04-15 Univ North Carolina State Für fructooligosaccharid-nutzende verbindungen codierende nukleinsäuren aus lactobacillus acidophilus und verwendungen davon
CA2530284A1 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US7442785B2 (en) 2003-07-24 2008-10-28 The University Of Kentucky Research Foundation Sesquiterpene synthase gene and protein
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2004275828B2 (en) 2003-09-23 2010-04-29 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
JP4777251B2 (ja) 2003-10-14 2011-09-21 バクスター・インターナショナル・インコーポレイテッド ビタミンｋエポキシド還元酵素複合体サブユニット１ｖｋｏｒｃ１、クマリンおよびその誘導体の治療標的
NZ547558A (en) 2003-11-17 2009-06-26 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
PL1704234T3 (pl) 2003-11-21 2012-06-29 Nps Pharma Inc Wytwarzanie glukagonopodobnego peptydu 2 i analogów
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
US7459289B2 (en) 2004-03-08 2008-12-02 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
WO2005100387A1 (en) 2004-04-07 2005-10-27 The University Of Chicago Monomeric red fluorescent proteins
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
KR20070039593A (ko) 2004-07-21 2007-04-12 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
CN101175508A (zh) 2004-10-21 2008-05-07 惠氏公司 表皮葡萄球菌多肽抗原的免疫原性组合物
AU2005318999B2 (en) 2004-12-22 2012-07-19 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
DK1828224T3 (en) 2004-12-22 2016-07-18 Ambrx Inc Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
CA2602175C (en) 2005-03-21 2012-11-27 Applera Corporation Alpha ketoamide compounds as cysteine protease inhibitors
JP2008537885A (ja) 2005-04-15 2008-10-02 ノース・キャロライナ・ステイト・ユニヴァーシティ 細菌の付着およびストレス耐性を修飾する方法および組成物
WO2006117565A2 (en) 2005-05-04 2006-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
EP1871163A2 (en) 2005-06-06 2008-01-02 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2007016319A2 (en) 2005-07-29 2007-02-08 Targeted Growth, Inc. Dominant negative mutant krp protein protection of active cyclin-cdk complex inhibition by wild-type krp
EP1922410A2 (en) 2005-08-15 2008-05-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1919931A4 (en) 2005-08-31 2010-01-20 Univ California CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
WO2007047583A2 (en) 2005-10-18 2007-04-26 National Jewish Medical And Research Center Conditionally immortalized long-term stem cells and methods of making and using such cells
US7749704B2 (en) 2005-11-01 2010-07-06 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the BLyS gene and use in diagnostic methods
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
JP2009516514A (ja) 2005-11-21 2009-04-23 ジェネンテック・インコーポレーテッド 新規遺伝子破壊、それらに関する組成物および方法
US8026354B2 (en) 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DE602007012412D1 (de) 2005-12-22 2011-03-24 Genentech Inc Rekombinante produktion heparinbindender proteine
JP2009527227A (ja) 2006-02-17 2009-07-30 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2027291A2 (en) 2006-04-27 2009-02-25 Pikamab, Inc. Methods and compositions for antibody therapy
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
CA2656558A1 (en) 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
NZ576445A (en) 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
EP2140021B1 (en) 2007-02-22 2012-01-11 Genentech, Inc. Methods for detecting inflammatory bowel disease
DK2068909T3 (da) 2007-03-30 2012-08-06 Ambrx Inc Modificerede FGF-21-polypeptider og anvendelse heraf
US8071741B2 (en) 2007-04-20 2011-12-06 Defiante Farmaceutica, S.A. Stable recombinant adenosine deaminase
CA2683423C (en) 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
KR101486615B1 (ko) 2007-07-16 2015-01-28 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
CA2692819A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
CA2971794C (en) 2007-10-04 2020-03-24 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
US20090233990A1 (en) 2007-11-01 2009-09-17 Hee Cheol Cho Generation of biological pacemaker activity
US8679749B2 (en) 2007-11-01 2014-03-25 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2586797A3 (en) 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
US8003325B2 (en) 2007-11-30 2011-08-23 Mayo Foundation For Medical Education And Research Polymorphisms of the BLyS gene and use in diagnostic methods
EP4427805A3 (en) 2008-01-31 2024-12-18 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
ES2640533T3 (es) 2008-04-09 2017-11-03 Genentech, Inc. Composiciones y métodos novedosos para el tratamiento de enfermedades relacionadas con la inmunidad
AU2009246876B2 (en) 2008-05-16 2015-04-02 Htyr Acquisition Llc Antibodies and processes for preparing the same
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
CA2738033C (en) 2008-09-26 2019-11-26 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
MX346001B (es) 2008-09-26 2017-03-01 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
US9702877B2 (en) 2008-10-31 2017-07-11 Quest Diagnostics Investments Incorporated BCR-ABL variants
EP2361093A2 (en) 2008-11-26 2011-08-31 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
EP3581579A1 (en) 2009-02-03 2019-12-18 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
EP2251025A1 (en) 2009-05-12 2010-11-17 Universitat Autònoma De Barcelona Use of inclusion bodies as therapeutic agents
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
LT2440241T (lt) 2009-06-08 2017-10-10 Amunix Operating Inc. Augimo hormonų polipeptidai ir jų gamybos bei panaudojimo būdai
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
EP2448593B1 (en) 2009-07-03 2020-11-25 Bionor Immuno AS Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
EP2470670A4 (en) 2009-08-24 2013-07-10 Amunix Operating Inc COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
US9488656B2 (en) 2009-09-30 2016-11-08 Quest Diagnostics Investments Incorporated BCR-ABL truncation mutations
US20120219952A1 (en) 2009-10-06 2012-08-30 Patrice Nordmann Carbapenemase and antibacterial treatment
BR112012008907A2 (pt) 2009-10-15 2020-11-24 Genentech, Inc fatores de crescimento de fibroblastos quiméricos com especificidade receptora alterada
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
MX338694B (es) 2009-11-30 2016-04-27 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
WO2011087808A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
PH12012501680A1 (en) 2010-02-23 2012-11-05 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
MX342239B (es) 2010-05-03 2016-09-21 Genentech Inc * Composiciones y metodos para el diagnostico y tratamiento de tumores.
JP5871911B2 (ja) 2010-05-19 2016-03-01 ノース カロライナ ステート ユニバーシティ 治療用ペプチドの送達のための組成物および方法
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
CN103037887B (zh) 2010-06-25 2017-11-10 国家医疗保健研究所 用于治疗呼吸道感染的方法和药物组合物
RU2754957C2 (ru) 2010-07-29 2021-09-08 Буззард Фармасьютикалз Аб Агонисты и антагонисты гибридного рецептора il-1 i типа
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AU2011291943B2 (en) 2010-08-17 2015-01-22 Ambrx, Inc. Modified relaxin polypeptides and their uses
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
US8729233B2 (en) 2010-08-30 2014-05-20 Board Of Trustees Of Michigan State University Microbial nanowires and products related thereto
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
AU2011302522A1 (en) 2010-09-15 2013-05-02 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2441776A1 (en) 2010-10-15 2012-04-18 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain
WO2012049328A1 (en) 2010-10-15 2012-04-19 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
US8603740B2 (en) 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
WO2012095684A1 (en) 2011-01-10 2012-07-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for the screening of substances useful for the prevention and treatment of neisseria infections
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2013011072A1 (en) 2011-07-20 2013-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Carbapenemase and antibacterial treatment
EP2736524A1 (en) 2011-07-29 2014-06-04 Eleven Biotherapeutics, Inc. Purified proteins
WO2013033456A2 (en) 2011-09-02 2013-03-07 Board Of Trustees Of Michigan State University Microbial nanowires and methods of making and using
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
KR102008190B1 (ko) 2012-02-15 2019-08-07 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
DK2814840T3 (da) 2012-02-15 2020-02-03 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
SG10201700340WA (en) 2012-02-27 2017-03-30 Amunix Operating Inc Xten conjugate compositions and methods of making same
HRP20171966T1 (hr) 2012-03-27 2018-02-09 F. Hoffmann - La Roche Ag Postupak za proizvodnju rekombinantnih proteina s niskim razinama dhna (1,4-dihidroksi-2-naftoata)
PT2841087T (pt) 2012-04-27 2017-11-27 Us Health Antagonistas de fator de crescimento endotelial vascular e métodos para utilização dos mesmos
JP6298044B2 (ja) 2012-05-03 2018-03-20 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）類似体
EP3967323A3 (en) 2012-06-06 2022-05-04 Bionor Immuno AS Hiv vaccine
AU2013292330B2 (en) 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
EP2922871B1 (en) 2012-11-20 2019-06-19 The University of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
US9879245B2 (en) 2012-12-07 2018-01-30 Danisco Us Inc. Polypeptides having beta-mannanase activity and methods of use
EP2929022B1 (en) 2012-12-07 2016-11-09 Danisco US Inc. Compositions and methods of use
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
SG11201507447PA (en) 2013-03-13 2015-10-29 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
EP2968495B1 (en) 2013-03-15 2019-07-03 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
MX368005B (es) 2013-03-15 2019-09-13 Genentech Inc Polipéptidos de il-22 y proteínas de fusion de il-22 fc y métodos de uso.
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
RU2016117275A (ru) 2013-11-01 2017-12-04 Сфериум Биомед С.Л. Тельца включения для трансдермальной доставки терапевтических и косметических средств
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
MX377605B (es) 2014-03-14 2025-03-10 Daniel J Capon Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
US20170165321A1 (en) 2014-07-11 2017-06-15 Bionor Immuno As Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
US20170211054A1 (en) 2014-09-30 2017-07-27 Dansico Us Inc. Compositions comprising beta mannanase and methods of use
WO2016054176A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
US20170218351A1 (en) 2014-09-30 2017-08-03 Danisco Us Inc. Compositions comprising beta-mannanase and methods of use
WO2016054194A1 (en) 2014-09-30 2016-04-07 1/1Danisco Us Inc Compositions comprising beta-mannanase and methods of use
WO2016054168A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta mannanase and methods of use
EA036697B1 (ru) 2014-10-24 2020-12-09 Бристол-Майерс Сквибб Компани Модифицированные полипептиды fgf-21 и их применение
WO2016100825A1 (en) 2014-12-18 2016-06-23 Danisco Us Inc Engineered multifunctional enzymes and methods of use
EP3234119A1 (en) 2014-12-18 2017-10-25 Danisco US Inc. Engineered multifunctional enzymes and methods of use
CN107531774B (zh) 2015-02-06 2021-12-14 北卡罗来纳大学查珀尔希尔分校 优化的人类凝血因子viii基因表达盒及其用途
ES2752054T3 (es) 2015-03-31 2020-04-02 Novimmune Sa Método para optimizar el ensamble y producción de complejos de proteínas heteromultiméricas
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
HK1248162A1 (zh) 2015-08-03 2018-10-12 Bioverativ Therapeutics Inc. 因数ix融合蛋白以及其制备及使用方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MX394122B (es) 2016-03-29 2025-03-24 Geltor Inc Expresión de proteínas en bacterias gram negativas en la que la relación del volumen periplasmático con respecto al volumen citoplasmático está entre 0.5:1 y 10:1
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
US10590426B2 (en) 2016-08-22 2020-03-17 Board Of Trustees Of Michigan State University Genetic control of cell size
EP4242298A2 (en) 2016-12-02 2023-09-13 Taiga Biotechnologies, Inc. Nanoparticle formulations
CA3046207A1 (en) 2016-12-06 2018-06-14 Kaleido Biosciences, Inc. Glycan polymers and related methods thereof
IL250479A0 (en) 2017-02-06 2017-03-30 Sorek Rotem Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
DK3490584T3 (da) 2017-08-03 2022-01-31 Taiga Biotechnologies Inc Fremgangsmåder og sammensætninger til behandlingen af melanom
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
JP7345479B2 (ja) 2018-01-26 2023-09-15 ジェネンテック， インコーポレイテッド 組成物及び使用方法
JP7349995B2 (ja) 2018-01-26 2023-09-25 ジェネンテック， インコーポレイテッド ＩＬ－２２ Ｆｃ融合タンパク質及び使用方法
MA51907A (fr) 2018-02-21 2021-05-26 Hoffmann La Roche Posologie pour un traitement avec des protéines de fusion il-22 fc
IL258467A (en) 2018-03-29 2018-07-04 Ilana Kolodkin Gal Methods of disrupting a biofilm and/or preventing formation of same
KR20200140878A (ko) 2018-04-09 2020-12-16 암젠 인크 성장 분화 인자 15 융합 단백질
ES3034016T3 (en) 2018-05-18 2025-08-12 Bioverativ Therapeutics Inc Methods of treating hemophilia a
WO2019234187A1 (en) 2018-06-06 2019-12-12 Leadartis, S.L. Trimeric polypeptide complexes and uses thereof
MX2021002575A (es) 2018-09-11 2021-06-08 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
US12419902B2 (en) 2019-03-31 2025-09-23 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
CA3132857A1 (en) 2019-04-08 2020-10-15 Yosef Refaeli Compositions and methods for the cryopreservation of immune cells
SG11202111349QA (en) 2019-04-12 2021-11-29 Geltor Inc Recombinant elastin and production thereof
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion
KR102134418B1 (ko) * 2019-06-17 2020-07-16 씨제이제일제당 주식회사 L-타이로신을 생산하는 미생물 및 이를 이용한 l-타이로신 생산 방법
US20210070811A1 (en) 2019-09-05 2021-03-11 Board Of Trustees Of Michigan State University Method for protein nanowire synthesis and tunable control of nanowire length
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
US12527875B2 (en) 2020-02-19 2026-01-20 Evive Biotechnology (Shanghai) Ltd Methods for treating graft versus host disease
CN115243726B (zh) 2020-03-11 2025-07-15 北京泰德制药股份有限公司 白介素-2多肽偶联物及其使用方法
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2022038539A2 (en) 2020-08-18 2022-02-24 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
US12448633B2 (en) 2021-08-06 2025-10-21 The Board Of Trustees Of The University Of Alabama Bacterial N-demthylases as biocatalysts for the production of methylxanthines
IL288680A (en) 2021-12-05 2023-07-01 Yeda Res & Dev Genetically modified phages and their use
EP4638773A1 (en) 2022-12-23 2025-10-29 Thermo Fisher Scientific Baltics Uab Closed system for expressing recombinant proteins using e. coli and methods for producing clarified cell cultures thereof
WO2024175788A2 (en) 2023-02-23 2024-08-29 Micropep Technologies S.A. Methods and compositions for production and purification of peptides
WO2025215636A1 (en) 2024-04-08 2025-10-16 Yeda Research And Development Co. Ltd. Anti-defense system polypeptides and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
IL55892A (en) * 1977-11-08 1983-10-31 Genentech Inc Cloning vehicle for transforming microbial host to render it capable of polypeptide expression,and products therefrom
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4631257A (en) 1978-12-26 1986-12-23 Cetus Corporation Stable high copy number plasmids
FI793884A7 (fi) * 1978-12-26 1981-01-01 Cetus Corp Vakaita runsaasti jäljentyviä plasmideja.
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
GB2052516B (en) * 1979-06-01 1983-06-29 Searle & Co Plasmid vectors production and use thereof
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DK33181A (da) * 1980-02-06 1981-08-07 Searle & Co Fremgangsmaade til fremstilling af et interferonlignende protein
CH651308A5 (de) * 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
IT1139487B (it) * 1980-09-25 1986-09-24 Genentech Inc Produzione microbica di interferone di fibroblasti umani
JPS5780398A (en) * 1980-11-05 1982-05-19 Sanraku Inc Plasmid produced by genetic manipulation, coliform bacillus having the same and preparation of tryptophan with said bacillus
DK489481A (da) * 1980-11-10 1982-05-11 Searle & Co Plasmidvektor og frmgangsmaade til fremstilling deraf
US5145782A (en) * 1980-12-08 1992-09-08 The Regents Of The University Of California DNA expression vector suitable for direct expression of a foreign gene
EP0054330B1 (en) * 1980-12-12 1986-09-17 Unilever N.V. Dna sequences encoding various allelic forms of mature thaumatin, recombinant plasmids comprising said dna's and a process for their preparation, bacterial cultures comprising said recombinant plasmids, and method for producing mature thaumatin

Also Published As

Publication number Publication date
YU45534B (en) 1992-05-28
KR830005351A (ko) 1983-08-13
HU195534B (en) 1988-05-30
PH20736A (en) 1987-04-02
DK173085B1 (da) 1999-12-27
DE3153606C2 (enExample) 1991-04-25
NO843719L (no) 1981-09-25
EP0036776A2 (en) 1981-09-30
PH20110A (en) 1986-09-29
DD204494A5 (de) 1983-11-30
IE810636L (en) 1981-09-24
GR74818B (enExample) 1984-07-12
PH18915A (en) 1985-11-06
PL147727B1 (en) 1989-07-31
MY8500896A (en) 1985-12-31
NO165644C (no) 1991-03-13
CS238645B2 (en) 1985-12-16
FR2555199A1 (fr) 1985-05-24
ZW5481A1 (en) 1981-10-21
PH17537A (en) 1984-09-19
NZ207659A (en) 1985-12-13
JPH05211885A (ja) 1993-08-24
AU2996484A (en) 1984-10-18
CA1213539A (en) 1986-11-04
AU585832B2 (en) 1989-06-29
KR860001230B1 (ko) 1986-08-30
FI72344B (fi) 1987-01-30
ES8304206A1 (es) 1983-03-16
AR248050A1 (es) 1995-05-31
PT72716A (en) 1981-04-01
DK129981A (da) 1981-09-25
JPH0724582B2 (ja) 1995-03-22
ATE52802T1 (de) 1990-06-15
PL230296A1 (enExample) 1982-01-18
FI853488A0 (fi) 1985-09-12
YU75681A (en) 1985-03-20
NO165644B (no) 1990-12-03
NO810986L (no) 1981-09-25
DZ278A1 (fr) 2004-09-13
PL162227B1 (pl) 1993-09-30
ES8207220A1 (es) 1982-09-16
NO161572C (no) 1989-08-30
FI853489A0 (fi) 1985-09-12
DE3176205D1 (en) 1987-06-25
AU542640B2 (en) 1985-02-28
FI853488L (fi) 1985-09-12
IL71885A (en) 1986-01-31
US5888808A (en) 1999-03-30
JPH0673469B2 (ja) 1994-09-21
ZA811368B (en) 1982-04-28
IT8167406A0 (it) 1981-03-23
AU6863681A (en) 1981-10-01
DE3111405A1 (de) 1982-03-25
NO843718L (no) 1981-09-25
FI810876L (fi) 1981-09-25
FR2480781A1 (fr) 1981-10-23
GB2073203B (en) 1984-02-29
PT72716B (en) 1982-03-19
IE51892B1 (en) 1987-04-29
EP0036776A3 (en) 1982-10-27
BG45220A3 (bg) 1989-04-14
CS238646B2 (en) 1985-12-16
EP0086548A3 (en) 1983-11-30
NO161572B (no) 1989-05-22
OA06774A (fr) 1982-06-30
ES509936A0 (es) 1983-04-01
CS238612B2 (en) 1985-12-16
FR2555199B1 (fr) 1987-09-04
BG42526A3 (bg) 1987-12-15
EP0086548A2 (en) 1983-08-24
JPH05268962A (ja) 1993-10-19
JPH0734747B2 (ja) 1995-04-19
EP0154133A2 (en) 1985-09-11
IE810656L (en) 1981-09-25
AU580959B2 (en) 1989-02-09
FI853488A7 (fi) 1985-09-12
DD203746A5 (de) 1983-11-02
FI72344C (fi) 1987-05-11
IE51894B1 (en) 1987-04-29
CA1198068A (en) 1985-12-17
FI853489L (fi) 1985-09-12
MX7689E (es) 1990-08-14
FR2480781B1 (fr) 1985-10-18
IE860657L (en) 1981-09-24
NZ207660A (en) 1985-12-13
BR8101712A (pt) 1981-09-29
DE3176737D1 (en) 1988-06-16
IL62460A (en) 1986-01-31
ATE34183T1 (de) 1988-05-15
ATE27306T1 (de) 1987-06-15
ES500617A0 (es) 1982-09-16
EP0154133B1 (en) 1990-05-16
IT1144324B (it) 1986-10-29
YU26084A (en) 1989-02-28
IL71885A0 (en) 1984-09-30
EP0086548B1 (en) 1987-05-20
ES509935A0 (es) 1983-03-16
AU2996384A (en) 1984-10-18
DE3177179D1 (de) 1990-06-21
IL62460A0 (en) 1981-05-20
NZ196584A (en) 1985-12-13
IE51893B1 (en) 1987-04-29
DE3111405C2 (enExample) 1990-06-21
FI810876A7 (fi) 1981-09-25
GB2073203A (en) 1981-10-14
DD159435A5 (de) 1983-03-09
US6333174B1 (en) 2001-12-25
ES8305042A1 (es) 1983-04-01
JPS56145221A (en) 1981-11-11
EP0154133A3 (en) 1986-05-28
EP0036776B1 (en) 1988-05-11

Similar Documents

Publication Publication Date Title
BG46005A3 (bg) Метод за получаване на експресионен плазмид за експресия на хетероложен ген
US4374927A (en) Extrachromosomal regulation of expression
KR830005355A (ko) 박테리아숙주내에서 각종 폴리펩타이드를 합성하는 방법 및 폴리펩타이드 dna
AU553885B2 (en) Expression of exogenous polypeptides in yeast
KR850003163A (ko) 완전변이 표현 콘트롤 시스템
ES8305413A1 (es) Un metodo para estabilizar y seleccionar celulas huesped quecontienen un adn recombinante
ES474852A1 (es) Un metodo para la expresion,en un huesped bacteriano trans- formado de un polipeptido heterologo con respecto al huespeden su estado no transformado
EP0048970A3 (en) Polypeptides, process for their microbial production, intermediates therefor and compositions containing them
KR940021731A (ko) Crm 단백질 및 디프테리아 독소의 생산을 위한 방법 및 플라스미드
NO911138L (no) Bakterielle vektorer.
AU575784B2 (en) Swine growth hormone-like polypeptides
IE821174L (en) Microbial gene promoter/operator
DE69328514D1 (de) Herstellung rekombinanter Proteine unter Verwendung von Herpes-Virus-Promotoren und VP16-Transaktivatoren
DK0677110T4 (da) Rekombinant mælkesyrebakterie, der indeholder en inserteret promotor
EP0139501A3 (en) The manufacture and expression of genes for thaumatin
DK237985D0 (da) Genteknologisk fremgangsmaade til fremstilling af human-interleukin-2 og middel til gennemfoerelse af fremgangsmaaden
DE3071292D1 (en) Recombinant bacteriophage for heterologous cloning of bacillus microorganisms and method for its production
EP0060045A3 (en) Stable high copy number plasmids, method for their formation and their use in protein production
ATE72832T1 (de) Rekombinante plasmide, diese rekombinante plasmide enthaltende bakterien, verfahren zur herstellung von fermentierten nahrungsmitteln, tierfutter, bestandteile derseben oder proteinen unter verwendung dieser bakterien.
AU4394385A (en) Novel vector comprising DNA sequences from the Bombyx mori nuclear polyhedrosis virus, and the use of said vector to produce gene products by genetic engineering
DE3484078D1 (de) Uebertragbare induzierbare kontrollsysteme, diese enthaltende expressionsvektoren, mit diesen transformierte mikroorganismen und ihre verwendung bei der expression von exogenem protein.
DE3280060D1 (de) Verfahren zum produzieren von protein aus einem mikroorganismus, mikroorganismen zur verwendung in solchem verfahren und ihre erzeugung, vektoren zur verwendung in dieser erzeugung und protein produziert durch diesen mikroorganismus und von diesen mikroorganismen abgeleitete transformierte kulturen.
AU531722B2 (en) Stable high copy number plasmids
Vernet et al. Stable maintenance in chemostat-grown Escherichia coli of pBR322 and pACYC184 by disruption of the tetracycline resistance gene
IE881779L (en) Dna fragments, containing a lactic acid bacterium-specific¹regulator region for the expression of genes coding for¹normally heterologous proteins, recombinant plasmids based¹on such dna fragments, lactic acid bacteria which contain¹these recombinant plasmids and the heterologous proteins and¹products prepared with the aid of the above microorganisms